Vapaliximab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (mouse/human) |
| Target | VAP-1 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
  (what is this?) (verify) | |
Vapaliximab is a chimeric monoclonal antibody[1] and an experimental immunosuppressive drug.[2] Development was discontinued by 2012.[3]
References
- ^ "Recommended INN: List 49 International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 17 (2). 2003. Archived from the original on 2009-10-16. Retrieved 2021-12-12.
{{cite journal}}: CS1 maint: bot: original URL status unknown (link) - ^ Panebianco M, Walker L, Marson AG (October 2023). "Immunomodulatory interventions for focal epilepsy". The Cochrane Database of Systematic Reviews. 10 (10): CD009945. doi:10.1002/14651858.CD009945.pub3. PMC 10577807. PMID 37842826.
- ^ "Vapaliximab". AdisInsight. Springer Nature Switzerland AG. Retrieved 2 January 2019.